Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Methyl 4-(8-(hydroxyamino)-8-oxooctanoyl)oxybenzoate
1. 946150-57-8
2. Remetinostat [usan]
3. Shp-141
4. Methylparaben Suberohydroxamic Acid Phenyl Ester
5. Methyl 4-((8-(hydroxyamino)-8-oxooctanoyl)oxy)benzoate
6. Nsc-748492
7. 37nt056at4
8. Benzoic Acid, 4-((8-(hydroxyamino)-1,8-dioxooctyl)oxy)-, Methyl Ester
9. Methyl 4-{[8-(hydroxyamino)-8-oxooctanoyl]oxy}benzoate
10. Unii-37nt056at4
11. Remetinostat (usan/inn)
12. Remetinostat [inn]
13. Remetinostat [who-dd]
14. Methyl 4-[8-(hydroxyamino)-8-oxooctanoyl]oxybenzoate
15. Chembl3707219
16. Schembl12682510
17. Dtxsid20647779
18. Shp-141shp-141
19. Bcp30561
20. Ex-a3219
21. Wmb15057
22. Nsc748492
23. Akos037649302
24. Db14869
25. Nsc 748492
26. Bs-17956
27. Db-088836
28. Hy-100365
29. Cs-0018698
30. D10977
31. Shp-141; Shp 141; Shp141; Shape
32. Q27256692
33. Benzoic Acid,8-dioxooctyl]oxy]-, Methyl Ester (mp-shape)
| Molecular Weight | 323.34 g/mol |
|---|---|
| Molecular Formula | C16H21NO6 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 11 |
| Exact Mass | 323.13688739 g/mol |
| Monoisotopic Mass | 323.13688739 g/mol |
| Topological Polar Surface Area | 102 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 390 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Remetinostat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Remetinostat, including repackagers and relabelers. The FDA regulates Remetinostat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Remetinostat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Remetinostat supplier is an individual or a company that provides Remetinostat active pharmaceutical ingredient (API) or Remetinostat finished formulations upon request. The Remetinostat suppliers may include Remetinostat API manufacturers, exporters, distributors and traders.
Remetinostat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Remetinostat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Remetinostat GMP manufacturer or Remetinostat GMP API supplier for your needs.
A Remetinostat CoA (Certificate of Analysis) is a formal document that attests to Remetinostat's compliance with Remetinostat specifications and serves as a tool for batch-level quality control.
Remetinostat CoA mostly includes findings from lab analyses of a specific batch. For each Remetinostat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Remetinostat may be tested according to a variety of international standards, such as European Pharmacopoeia (Remetinostat EP), Remetinostat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Remetinostat USP).
LOOKING FOR A SUPPLIER?
